Aligos Therapeutics (ALGS) Current Deferred Revenue (2020 - 2025)
Aligos Therapeutics' (ALGS) quarterly Current Deferred Revenue came in at $168000.0 in Q3 2025, down 70.98% on a QoQ basis from $579000.0 in Q2 2025.
Aligos Therapeutics (ALGS) Current Deferred Revenue (2020 - 2025) Analysis & Trends
Aligos Therapeutics (ALGS) has 6 years of Current Deferred Revenue data on file, last reported at $168000.0 in Q3 2025.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $168000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $168000.0 (changed N/A YoY) and the FY2024 annual result came in at $151000.0, down 88.46% from the prior year.
- Current Deferred Revenue slipped to $168000.0 in Q3 2025, from $579000.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $15.1 million in Q1 2022 to a low of $151000.0 in Q4 2024.
- A 5-year average of $6.1 million and a median of $6.6 million in 2021 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue soared 98.75% — and 2024, when it plunged 88.46%.
- Tracing ALGS's Current Deferred Revenue over 5 years: stood at $7.6 million in 2021, then gained by 14.42% to $8.7 million in 2022, then sank by 85.04% to $1.3 million in 2023, then sank by 88.46% to $151000.0 in 2024, then advanced by 11.26% to $168000.0 in 2025.
- The last three Current Deferred Revenue figures came in at $168000.0 (Q3 2025), $579000.0 (Q2 2025), and $151000.0 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - |
| 10 | Aligos Therapeutics | 70.20 Mn | 39.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 168,000.00 |
| Jun 30, 2025 | 579,000.00 |
| Dec 31, 2024 | 151,000.00 |
| Dec 31, 2023 | 1.31 Mn |
| Sep 30, 2023 | 2.09 Mn |
| Jun 30, 2023 | 4.10 Mn |
| Mar 31, 2023 | 6.56 Mn |
| Dec 31, 2022 | 8.74 Mn |
| Sep 30, 2022 | 10.73 Mn |
| Jun 30, 2022 | 13.13 Mn |
| Mar 31, 2022 | 15.07 Mn |
| Dec 31, 2021 | 7.64 Mn |
| Sep 30, 2021 | 6.64 Mn |
| Jun 30, 2021 | 6.81 Mn |
| Mar 31, 2021 | 7.58 Mn |
| Dec 31, 2020 | 7.89 Mn |